1-2 of 2
Donghang Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Martin Hutchings, Anna Sureda Balari, Francesc Bosch, Thomas Stauffer Larsen, Paolo Corradini, Abraham Avigdor, María José Terol, Antonio Rueda Dominguez, Antonio Pinto, Alan P Skarbnik, Raul Cordoba, Judit Mészáros Joergensen, Pier Luigi Zinzani, Ronit Gurion, Neta Goldschmidt, Wilfred Leung, Donghang Li, James Relf, Maneesh Tandon, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2024) 144 (Supplement 1): 988.
https://doi.org/10.1182/blood-2024-194328
Published: 2024
Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Martin Hutchings, Abraham Avigdor, Anna Maria Sureda Balari, Maria José Terol, Francesc Bosch, Paolo Corradini, Thomas S. Larsen, Antonio Rueda Dominguez, Alan Skarbnik, Judit Mészáros Joergensen, David Lavie, Ronit Gurion, Pier Luigi Zinzani, Antonio Pinto, Raul Cordoba, Alessia Bottos, Donghang Li, James Relf, Audrey Filézac De L'Étang, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2023) 142 (Supplement 1): 4460.
https://doi.org/10.1182/blood-2023-174213
Published: 2023